Developer docs
API playgroundTry for free, no card

Search company profiles

Maiva Pharma

Full company profile

uuid0002b8b

Namestring
Maiva Pharma
Legal namestring
Maiva Pharma Pvt. Ltd.
Websiteurl
maivapharma.com
Company typeenum
Private
Founded yearint
1996
Descriptiontext

Maiva Pharma (legal entity: Maiva Pharma Pvt. Ltd.) is a Bengaluru-headquartered, privately held Contract Development and Manufacturing Organization (CDMO) specializing in sterile liquid injectable formulations, including small-volume glass vials, ampoules, and large-volume glass bottles. Founded in 1996 and operating a manufacturing facility footprint of 501-1,000 employees, the company is recognized as India's second-largest pure-play injectables CDMO. Its customer base spans global pharmaceutical and biotechnology companies, with a strategic emphasis on regulated markets and the US hospital channel.

The company's core technical platform centers on advanced isolator-based sterile manufacturing systems, integrated in-house quality control and microbiology laboratories, and multi-format dosage capability spanning vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations. A new 22-acre manufacturing facility in Shoolagiri, Tamil Nadu was inaugurated in June 2026 with three commissioned manufacturing lines in Phase 1 and a planned expansion to six lines. Maiva's strategic US-market anchor is its manufacturing partnership with Breckenridge Pharmaceutical (a Towa International subsidiary) for sterile injectables serving US hospitals.

Maiva generates revenue through contract development and manufacturing fees earned under long-term supply agreements with pharmaceutical partners, a B2B model in which it manufactures products on behalf of clients who handle downstream commercialization and distribution. The company raised approximately INR 1,000 crores (~$120 million) in 2024 from Morgan Stanley Private Equity Asia and InvAscent's India Life Sciences Fund IV through primary and secondary funding, giving those sponsors a controlling stake. Leadership consists of Bhaskar Krishna as Managing Director and CEO.

Short descriptiontext

Maiva Pharma is an Indian injectables CDMO and India's second-largest pure-play sterile injectable manufacturer, serving global pharmaceutical companies with vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations for regulated markets, especially the US hospital channel.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
501–1,000
akta.pro rankint
HeadquartersHosur, India
HQ citystring
Hosur
HQ countrystring
India
HQ regionstring
Asia
Markets served

Serves global market

Offices3 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
sterile injectable manufacturing, pharmaceutical CDMO services, contract manufacturing organization, lyophilized formulations production, pre-filled syringe manufacturing
Industry4 codes
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
NAICS code2 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Pharmaceutical CDMO / Sterile Injectable Manufacturing
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Contract Manufacturing Services
TypeOne Time License
Description

Maiva Pharma generates revenue as a Contract Development and Manufacturing Organization (CDMO), providing sterile injectable manufacturing services to pharmaceutical and biotechnology companies. The company develops and manufactures injectable products on behalf of clients, earning fees for manufacturing services typically under long-term supply agreements.

economictimes.indiatimes.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Maiva Pharma operates as a pure-play injectables Contract Development and Manufacturing Organization (CDMO), specializing in the development and commercial manufacturing of sterile injectable dosage forms including vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations. The company serves global pharmaceutical and biotechnology partners with manufacturing capacity focused on regulated markets, particularly the US.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Phase 1 facility features three dedicated manufacturing lines with capacity to expand to six total lines
Product overview1 text field

Maiva Pharma is an Indian injectables CDMO (Contract Development and Manufacturing Organization) and India's second-largest pure-play injectables CDMO, based in Bengaluru. The company operates a 22-acre manufacturing facility in Shoolagiri, Tamil Nadu, with capabilities in sterile injectable dosage forms. Phase 1 of the facility features three dedicated manufacturing lines for vials, pre-filled syringes, cartridges, and lyophilized formulations using advanced isolator-based manufacturing systems. The company's core service offerings include sterile injectables manufacturing services for global regulated markets, with a strategic focus on the U.S. hospital market through its partnership with Breckenridge Pharmaceutical.

Product and service2 records
1Sterile Injectables Manufacturing Services
CategoryContract Manufacturing Services
2US Hospital Market Sterile Injectables
CategoryContract Manufacturing Services
Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-03-11
Description

Strategic manufacturing partnership focused on sterile injectable products for the U.S. hospital market. Maiva serves as a key manufacturing partner for several injectable products, strengthening Breckenridge's position as a reliable supplier to hospitals and clinics nationwide. This collaboration represents a milestone in Breckenridge's evolution into specialty, hospital, and retail business lines.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Piramal Pharma Solutions is an Indian CDMO with significant sterile injectable fill-finish capacity serving global regulated markets. Directly comparable as a domestic Indian sterile injectables CDMO targeting the same US/EU customer base.

2Syngene International
TypeRegional player
Description

Syngene is a leading Indian CRO/CDMO with biologics and small-molecule manufacturing, including sterile injectable capabilities. Comparable as an Indian-headquartered CDMO serving global pharma with regulated-market manufacturing.

TypeDirect peer
Description

Aurobindo is one of India's largest generic injectable manufacturers with US-approved facilities supplying the US hospital market. Highly comparable to Maiva in pure-play injectables and US-regulated market exposure.

TypeBroad incumbent
Description

Catalent is a global CDMO with extensive sterile fill-finish capacity across vials, syringes, and cartridges. Comparable as a broad incumbent serving pharma customers in regulated markets with overlapping sterile injectable offerings.

TypeBroad incumbent
Description

Lonza is a global CDMO leader with aseptic fill-finish and sterile manufacturing capabilities for injectables. Comparable as a broad incumbent in sterile injectables CDMO serving global pharma and biotech customers.

6Recipharm
TypeBroad incumbent
Description

Recipharm is a European-headquartered CDMO with sterile injectable fill-finish services. Comparable as a broad incumbent in aseptic manufacturing serving regulated pharmaceutical markets.

TypeRegional player
Description

Hikal is an Indian CDMO with API and finished dosage manufacturing including injectables. Comparable as an India-based contract manufacturer serving global pharma customers.

TypeBroad incumbent
Description

Aenova is a European CDMO with sterile liquid and lyophilized injectable manufacturing capabilities. Comparable as a broad incumbent offering sterile fill-finish services to pharma partners in regulated markets.

9Evonik Health Care
TypeOthers
Description

Evonik provides CDMO services including aseptic fill-finish for complex injectable formulations. Comparable as a contract manufacturer with overlapping sterile injectable capabilities serving pharma customers.

TypeBroad incumbent
Description

Thermo Fisher's Patheon CDMO business includes sterile injectable manufacturing services globally. Comparable as a broad incumbent with overlapping aseptic fill-finish and lyophilization capabilities.

Market position
Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature3 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Maiva Pharma

Pharmaceutical CDMO / Sterile Injectable Manufacturingmaivapharma.com

Maiva Pharma is an Indian injectables CDMO and India's second-largest pure-play sterile injectable manufacturer, serving global pharmaceutical companies with vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations for regulated markets, especially the US hospital channel.

What Maiva Pharma does

Maiva Pharma (legal entity: Maiva Pharma Pvt. Ltd.) is a Bengaluru-headquartered, privately held Contract Development and Manufacturing Organization (CDMO) specializing in sterile liquid injectable formulations, including small-volume glass vials, ampoules, and large-volume glass bottles. Founded in 1996 and operating a manufacturing facility footprint of 501-1,000 employees, the company is recognized as India's second-largest pure-play injectables CDMO. Its customer base spans global pharmaceutical and biotechnology companies, with a strategic emphasis on regulated markets and the US hospital channel.

The company's core technical platform centers on advanced isolator-based sterile manufacturing systems, integrated in-house quality control and microbiology laboratories, and multi-format dosage capability spanning vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations. A new 22-acre manufacturing facility in Shoolagiri, Tamil Nadu was inaugurated in June 2026 with three commissioned manufacturing lines in Phase 1 and a planned expansion to six lines. Maiva's strategic US-market anchor is its manufacturing partnership with Breckenridge Pharmaceutical (a Towa International subsidiary) for sterile injectables serving US hospitals.

Maiva generates revenue through contract development and manufacturing fees earned under long-term supply agreements with pharmaceutical partners, a B2B model in which it manufactures products on behalf of clients who handle downstream commercialization and distribution. The company raised approximately INR 1,000 crores (~$120 million) in 2024 from Morgan Stanley Private Equity Asia and InvAscent's India Life Sciences Fund IV through primary and secondary funding, giving those sponsors a controlling stake. Leadership consists of Bhaskar Krishna as Managing Director and CEO.

Maiva Pharma firmographics

Firmographics
Name
Maiva Pharma
Legal name
Maiva Pharma Pvt. Ltd.
Website
https://maivapharma.com
Company type
Private
Founded year
1996
Operating status
Operating
Headcount range
501–1,000 employees
Short description
Maiva Pharma is an Indian injectables CDMO and India's second-largest pure-play sterile injectable manufacturer, serving global pharmaceutical companies with vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations for regulated markets, especially the US hospital channel.
Ownership category
akta.pro rank

Maiva Pharma industry classification

Industry
Product category
Pharmaceutical CDMO / Sterile Injectable Manufacturing
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAB
Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAK
Clinical Trial Material (CTM) Manufacturing & Supply CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)

Keywords

  • Sterile injectable manufacturing
  • Pharmaceutical CDMO services
  • Contract manufacturing organization
  • Lyophilized formulations production
  • Pre-filled syringe manufacturing

Where Maiva Pharma is headquartered

Location

Headquarters

HQ city
Hosur
HQ country
India
HQ region
Asia

Offices3 records

Markets served

Maiva Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Infrastructure, Technology or R&D, Supply Chain

Revenue model

  1. Contract Manufacturing Services: Maiva Pharma generates revenue as a Contract Development and Manufacturing Organization (CDMO), providing sterile injectable manufacturing services to pharmaceutical and biotechnology companies. The company develops and manufactures injectable products on behalf of clients, earning fees for manufacturing services typically under long-term supply agreements.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels2 records

Maiva Pharma product offering

Product offering

Core offering

Maiva Pharma operates as a pure-play injectables Contract Development and Manufacturing Organization (CDMO), specializing in the development and commercial manufacturing of sterile injectable dosage forms including vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations. The company serves global pharmaceutical and biotechnology partners with manufacturing capacity focused on regulated markets, particularly the US.

Product overview

Maiva Pharma is an Indian injectables CDMO (Contract Development and Manufacturing Organization) and India's second-largest pure-play injectables CDMO, based in Bengaluru. The company operates a 22-acre manufacturing facility in Shoolagiri, Tamil Nadu, with capabilities in sterile injectable dosage forms. Phase 1 of the facility features three dedicated manufacturing lines for vials, pre-filled syringes, cartridges, and lyophilized formulations using advanced isolator-based manufacturing systems. The company's core service offerings include sterile injectables manufacturing services for global regulated markets, with a strategic focus on the U.S. hospital market through its partnership with Breckenridge Pharmaceutical.

Differentiator

Problem solved

Functional benefit

Products and services

  • Sterile Injectables Manufacturing Services
  • US Hospital Market Sterile Injectables

Quantifiable outcome

  • Phase 1 facility features three dedicated manufacturing lines with capacity to expand to six total lines

Companies that use Maiva Pharma

Customer profile

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Maiva Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature3 records

Maiva Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Breckenridge PharmaceuticalcoreStrategic or Co-development Partner · 11 March 2026Strategic manufacturing partnership focused on sterile injectable products for the U.S. hospital market. Maiva serves as a key manufacturing partner for several injectable products, strengthening Breckenridge's position as a reliable supplier to hospitals and clinics nationwide. This collaboration represents a milestone in Breckenridge's evolution into specialty, hospital, and retail business lines.

Scale indicators6 records

Recent moves7 records

Expansion highlights5 records

Maiva Pharma competitors and assessment

Company assessment

Direct peers

  • Piramal Pharma Solutions: Piramal Pharma Solutions is an Indian CDMO with significant sterile injectable fill-finish capacity serving global regulated markets. Directly comparable as a domestic Indian sterile injectables CDMO targeting the same US/EU customer base.
  • Aurobindo Pharma: Aurobindo is one of India's largest generic injectable manufacturers with US-approved facilities supplying the US hospital market. Highly comparable to Maiva in pure-play injectables and US-regulated market exposure.

Regional players

  • Syngene International: Syngene is a leading Indian CRO/CDMO with biologics and small-molecule manufacturing, including sterile injectable capabilities. Comparable as an Indian-headquartered CDMO serving global pharma with regulated-market manufacturing.
  • Hikal Ltd: Hikal is an Indian CDMO with API and finished dosage manufacturing including injectables. Comparable as an India-based contract manufacturer serving global pharma customers.

Broad incumbents

  • Catalent: Catalent is a global CDMO with extensive sterile fill-finish capacity across vials, syringes, and cartridges. Comparable as a broad incumbent serving pharma customers in regulated markets with overlapping sterile injectable offerings.
  • Lonza Group: Lonza is a global CDMO leader with aseptic fill-finish and sterile manufacturing capabilities for injectables. Comparable as a broad incumbent in sterile injectables CDMO serving global pharma and biotech customers.
  • Recipharm: Recipharm is a European-headquartered CDMO with sterile injectable fill-finish services. Comparable as a broad incumbent in aseptic manufacturing serving regulated pharmaceutical markets.
  • Aenova Group: Aenova is a European CDMO with sterile liquid and lyophilized injectable manufacturing capabilities. Comparable as a broad incumbent offering sterile fill-finish services to pharma partners in regulated markets.
  • Thermo Fisher Scientific (Patheon CDMO): Thermo Fisher's Patheon CDMO business includes sterile injectable manufacturing services globally. Comparable as a broad incumbent with overlapping aseptic fill-finish and lyophilization capabilities.

Others

  • Evonik Health Care: Evonik provides CDMO services including aseptic fill-finish for complex injectable formulations. Comparable as a contract manufacturer with overlapping sterile injectable capabilities serving pharma customers.

Market position

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Maiva Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Maiva Pharma leadership team

Management profile

Number of profiles

Profiles1 record

Maiva Pharma funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Maiva Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Maiva Pharma

What does Maiva Pharma do?

Maiva Pharma operates as a pure-play injectables Contract Development and Manufacturing Organization (CDMO), specializing in the development and commercial manufacturing of sterile injectable dosage forms including vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations. The company serves global pharmaceutical and biotechnology partners with manufacturing capacity focused on regulated markets, particularly the US.

Is Maiva Pharma a public or private company?

Maiva Pharma is a private company. It is classified as private equity controlled and is currently operating.

When was Maiva Pharma founded?

Maiva Pharma was founded in 1996. It employs 501 to 1,000 people.

Where is Maiva Pharma based?

Maiva Pharma is headquartered in Hosur, India, in the Asia region.

How does Maiva Pharma make money?

One revenue line is on record: contract Manufacturing Services.

Who are Maiva Pharma's main competitors?

Direct peers on record are Piramal Pharma Solutions and Aurobindo Pharma. Regional players are Syngene International and Hikal Ltd. Broad incumbents are Catalent, Lonza Group, Recipharm, Aenova Group and Thermo Fisher Scientific (Patheon CDMO). Evonik Health Care is listed as an others.

Does Maiva Pharma have an API?

No public API is recorded for Maiva Pharma.

What industry is Maiva Pharma in?

Maiva Pharma's product category is Pharmaceutical CDMO / Sterile Injectable Manufacturing. Its primary akta.pro industry code is HLAGABAH, Sterile Fill-Finish & Aseptic Manufacturing CDMO, with a secondary code of HLAGABAB, Small-Molecule Drug Product (Solid/Oral/Parenteral) CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Manufacturing Today IndiaMaiva Pharma opens new sterile injectables facility in IndiaMaiva Pharma inaugurated a new manufacturing facility in Shoolagiri, Tamil Nadu, India, spanning 22 acres and specializing in sterile injectables as a Contract Manufacturing Organisation. Phase 1 features three dedicated manufacturing lines for vials, pre-filled syringes, cartridges, and lyophilised formulations, with advanced quality control and isolator-based manufacturing systems. The facility aligns with Maiva Pharma's long-term strategy to enhance capabilities and strengthen its presence in global markets serving regulated markets.The TribuneMaiva Pharma Inaugurates New State-of-the-Art Sterile Injectable Manufacturing Facility at Shoolagiri, IndiaMaiva Pharma inaugurated its new manufacturing facility at Shoolagiri, Tamil Nadu, India, equipped to produce a wide range of sterile injectable dosage forms including vials, pre-filled syringes, cartridges, suspensions, and lyophilized formulations. The 22-acre site will eventually house six manufacturing lines, with three already commissioned in Phase 1, featuring advanced isolator-based technology and in-house quality control and microbiology laboratories. The expansion significantly increases Maiva Pharma's sterile injectable manufacturing capacity and positions the company to better serve global pharmaceutical and biotechnology partners.PR NewswireBreckenridge Pharmaceutical enters strategic partnership with Maiva Pharma Pvt. Ltd.Breckenridge Pharmaceutical, Inc., a U.S. subsidiary of Towa International, has entered a strategic partnership with Maiva Pharma Pvt. Ltd. to supply sterile injectable products primarily to U.S. hospitals and clinics. Maiva will serve as a key manufacturing partner for several injectable products, strengthening Breckenridge's position in the U.S. hospital market and supporting its evolution into three patient-focused business lines: specialty, hospital, and retail. The collaboration expands Breckenridge's capacity to provide critical medications nationwide while leveraging Maiva's three decades of sterile manufacturing expertise and two facilities in Bengaluru, India.BioSpaceBreckenridge Pharmaceutical enters strategic partnership with Maiva Pharma Pvt. Ltd.Breckenridge Pharmaceutical announced a strategic partnership with Maiva Pharma focused on sterile injectable products for the U.S. hospital market, with Maiva serving as a key manufacturing partner. The collaboration strengthens Breckenridge's position as a reliable supplier to hospitals and clinics nationwide while expanding patient access to affordable generic injectables. This partnership reflects Breckenridge's ongoing investment in the hospital pharmaceutical supply chain and represents a milestone in the company's evolution into three defined business lines: specialty, hospital, and retail.MorningstarBreckenridge Pharmaceutical enters strategic partnership with Maiva Pharma Pvt. Ltd.Breckenridge Pharmaceutical, the U.S. subsidiary of Towa International, announced a strategic partnership with Maiva Pharma Pvt. Ltd. focused on sterile injectable products for the U.S. hospital market. Maiva will serve as a key manufacturing partner for several injectable products, strengthening Breckenridge's position as a reliable supplier to hospitals and clinics nationwide. The collaboration represents a milestone in Breckenridge's evolution into three patient-focused business lines—specialty, hospital, and retail.InvascentInvAscent invests in Maiva PharmaInvAscent, in partnership with Morgan Stanley Private Equity Asia, has invested INR 10,000 Mn in Maiva Pharma, India's second-largest pure-play injectables CDMO. Maiva plans to utilize the funds to establish a new greenfield manufacturing facility near Hosur, expanding its capabilities in sterile dosage forms such as pre-filled syringes and oncology injectables.The Times of IndiaMaiva Pharma: Maiva Pharma raises Rs 1000 crore from Morgan Stanley Private Equity, InvAscent - The Economic TimesMaiva Pharma raised Rs 1,000 crore in a primary and secondary funding round led by Morgan Stanley Private Equity Asia and the India Life Sciences Fund IV (InvAscent), resulting in a combined stake of over 60% for the investors. The company plans to utilize the proceeds to establish a new manufacturing plant near Hosur, Karnataka, focusing on sterile dosage forms such as pre-filled syringes and oncology injectables. This investment follows Maiva's strong revenue growth of over 40% year-over-year and its existing regulatory approvals for supplying the US, Canada, and EU markets.AvendusAvendus Capital advises Maiva Pharma on its INR ~1,000 crores fundraise from Morgan Stanley Private Equity Asia and India Life Sciences FundMaiva Pharma, based in Bengaluru, India, announced it has raised approximately 1,000 crore INR from Morgan Stanley Private Equity Asia and India Life Sciences Fund IV, which acquired a controlling stake and infused primary capital. The funds will be used to establish a new manufacturing facility near Hosur with capabilities in sterile dosage forms including pre-filled syringes and injectables.